ELTD1
ELTD1 (EGF, latrophilin and seven transmembrane domain-containing 1), also known as adhesion G protein-coupled receptor L4 (ADGRL4), is a protein that in humans is encoded by the ELTD1 gene. This protein is a member of the adhesion G protein-coupled receptor (aGPCR) family, which plays a role in various biological processes including angiogenesis, cardiovascular development, and cancer progression. ELTD1 has garnered attention for its potential role in the regulation of endothelial cell function and blood vessel formation, making it a target of interest in the study of diseases characterized by abnormal vessel growth such as cancer, cardiovascular diseases, and retinopathy.
Function[edit | edit source]
ELTD1 is involved in the process of angiogenesis, which is the growth of new blood vessels from pre-existing vessels. It is expressed in endothelial cells, where it may influence cell signaling pathways that regulate vascular development and maintenance. The exact mechanisms by which ELTD1 contributes to these processes are still under investigation, but it is believed to play a role in endothelial cell signaling and migration, which are critical steps in angiogenesis.
Clinical Significance[edit | edit source]
The expression of ELTD1 has been found to be upregulated in various types of cancer, suggesting its involvement in tumor angiogenesis and the potential for ELTD1 to serve as a biomarker for cancer progression. Additionally, because of its role in blood vessel formation, ELTD1 is being studied as a potential therapeutic target in diseases where angiogenesis is dysregulated, such as in certain cancers, diabetic retinopathy, and other conditions characterized by excessive or insufficient blood vessel growth.
Research[edit | edit source]
Research on ELTD1 is focused on elucidating its biological functions and its potential as a therapeutic target. Studies have explored its expression in different types of tumors and its impact on tumor growth and metastasis. There is also interest in developing inhibitors of ELTD1 as a means to control angiogenesis in diseases where this process is detrimental.
See Also[edit | edit source]
- Adhesion G protein-coupled receptor
- Angiogenesis
- Cancer
- Cardiovascular diseases
- Diabetic retinopathy
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
